
==== Front
Drugs Real World Outcomes
Drugs Real World Outcomes
Drugs - Real World Outcomes
2199-1154
2198-9788
Springer International Publishing Cham

39127822
420
10.1007/s40801-024-00420-7
Original Research Article
Real-World Amount of Clotting Factor Products and Non-Factor Products Dispensed and Annual Medical Expenditures for Japanese Patients with Haemophilia A
http://orcid.org/0000-0001-8716-8890
Bingo Masato 1
http://orcid.org/0000-0003-0438-8957
Fukutake Katsuyuki 12
http://orcid.org/0000-0003-3964-4009
Togo Kanae 3
http://orcid.org/0000-0003-0466-5993
Xu Linghua 3
http://orcid.org/0000-0003-3234-9509
Alvir José Maria Jimenez 4
http://orcid.org/0000-0002-6357-2642
Winburn Ian 5
http://orcid.org/0000-0001-6230-6679
Karumori Toshiyuki Toshiyuki.karumori@pfizer.com

3
1 https://ror.org/00k5j5c86 grid.410793.8 0000 0001 0663 3325 Tokyo Medical University, Tokyo, Japan
2 https://ror.org/01639jx86 grid.416765.7 0000 0004 1764 8866 Ogikubo Hospital, Tokyo, Japan
3 grid.418567.9 0000 0004 1761 4439 Pfizer Japan Inc., Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Shibuya-ku, Tokyo, Japan
4 grid.410513.2 0000 0000 8800 7493 Pfizer Inc., New York, NY USA
5 grid.418566.8 0000 0000 9348 0090 Pfizer Ltd., Walton-on-the-Hill, Surrey UK
10 8 2024
10 8 2024
9 2024
11 3 541552
6 3 2024
© Pfizer Inc 2024
2024
https://creativecommons.org/licenses/by-nc/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Background

Treatment for haemophilia A has expanded from plasma-derived factor VIII (pdFVIII) and standard half-life (SHL) recombinant FVIII (rFVIII) to extended half-life (EHL) rFVIII and non-factor products that mimic FVIII activity.

Objective

To determine amounts of clotting factor concentrates (CFCs) and emicizumab dispensed and associated healthcare expenditures in Japanese patients with haemophilia A.

Methods

This retrospective, non-interventional, observational study analysed data from 2016 to 2020 from a large-scale, hospital-based administrative database. Patients had haemophilia A without inhibitors and ≥ 2 prescriptions of the same CFC or emicizumab.

Results

In total, 974 patients with haemophilia A (median age, 30.0 years; median follow-up, 3.7 years) were included. Outpatient use of EHL rFVIII and emicizumab increased, although pdFVIII/SHL rFVIII were still used over the study. Median annual total healthcare expenditures/patient increased from ¥9,200,230 in 2016 to ¥19,748,221 in 2020. Overall, the median annual drug expenditure/patient increased from ¥8,723,120 in 2016 to ¥18,051,689 in 2020. Drug expenditure was highest with emicizumab, with an increase in median annual expenditure/patient from 2018 (n = 4, ¥26,030,206) to 2020 (n = 107, ¥45,430,408). Overall, 233 patients (23.9%) switched from an SHL to an EHL product. Although amounts of FVIII prescribed increased in the 3 months after switching, overall, there was no noticeable difference before and after switching. Median total healthcare and FVIII product expenditures increased following switching.

Conclusions

Prescribing of EHL products increased over the study and healthcare expenditures increased for patients who switched from SHL to EHL rFVIII products.

Supplementary Information

The online version contains supplementary material available at 10.1007/s40801-024-00420-7.

http://dx.doi.org/10.13039/100004319 Pfizer issue-copyright-statement© Springer Nature Switzerland AG 2024
==== Body
pmcKey Points for Decision Makers

The standard of care for people with haemophilia A includes treatment with clotting factor concentrates (CFCs) or non-factor products, such as emicizumab. Given the need for long-term prophylaxis, it is important to understand the medical expenditures associated with the use of CFCs and non-factor products in real-world clinical practice.	
This study analysed real-world data from a hospital-based administrative database in Japan to investigate medical expenditures for patients with haemophilia A without inhibitors receiving plasma-derived factor VIII (pdFVIII), standard half-life (SHL) recombinant FVIII (rFVIII), extended half-life (EHL) rFVIII or emicizumab.	
From 2016 to 2020, median annual total healthcare expenditures per patient and median annual drug expenditures per patient increased. Prescribing of EHL rFVIII and emicizumab increased. Total healthcare expenditures and drug expenditures increased for patients who switched from SHL to EHL rFVIII products.	

Introduction

Factor VIII (FVIII) has a pivotal role in the intrinsic coagulation cascade, promoting and maintaining haemostasis after injury [1]. Haemophilia A results from deficiency or insufficiency in FVIII [2]. According to the World Federation of Hemophilia Annual Global Survey 2020, 165,379 patients worldwide have haemophilia A, with approximately 5500 residing in Japan [3].

Globally, FVIII replacement is still the standard of care for patients with haemophilia A, although use of novel non-factor replacement therapies is increasing [4]. Therapeutic options for patients with haemophilia A in Japan have expanded over recent years from plasma-derived FVIII (pdFVIII) and recombinant FVIII (rFVIII) products with a standard half-life (SHL) to extended half-life (EHL) rFVIII products. EHL rFVIII products approved in Japan include: damoctocog alfa pegol (launched in February 2019 [5]), efraloctocog alfa (launched in March 2015 [6]), rurioctocog alfa pegol (launched in June 2018 [7]) and turoctocog alfa pegol (launched in January 2020 [8]).

Non-factor products, such as antibodies that mimic FVIII activity, have also been developed [4]. For example, emicizumab, a bispecific, monoclonal antibody developed by a Japanese company that bridges activated factor IX and factor X to restore function of missing activated FVIII, was launched in May 2018 [9], offering broad experience in the Japanese population [10–12]. In phase 3 studies, emicizumab prophylaxis, administered subcutaneously once-weekly for patients with haemophilia A with FVIII inhibitors [13] or once-weekly or every 2 weeks for those without FVIII inhibitors [14], significantly lowered bleeding rate versus no prophylaxis. Other novel therapeutics—such as molecules that function by inhibiting antithrombin and tissue factor pathway inhibitors [15], as well as gene therapy—are likely to further diversify therapeutic options for patients with haemophilia A [16].

The dosage and associated dosing interval of SHL and EHL rFVIII products vary between patients owing to considerations, such as the patient’s pharmacokinetic profile, bleeding pattern, activity level, prescriber's input as well as the approved indication (e.g. prophylaxis, on-demand, surgery or immune tolerance induction) [17, 18]. Although EHL products enable longer intervals between doses and similar annualized bleeding rates compared with SHL products in studies conducted in several markets to date [19, 20], the expenditures for patients with haemophilia A using EHL versus SHL rFVIII products was consistently higher regardless of the dispensed FVIII dosage [21, 22]. Treatment to resolve breakthrough bleeds adds to healthcare expenditure, regardless of whether an EHL or SHL rFVIII product is used for prophylaxis; however, use of EHL rFVIII products have also been shown to be a cost-effective treatment option in one study conducted in Italy in patients with haemophilia A [23].

With the goal of managing costs, several countries have analysed the direct healthcare expenditures for patients with haemophilia [16, 24–29]. Understanding the use of clotting factor concentrates (CFCs) and non-factor products in real-world clinical practice is important given the need for long-term prophylaxis. This study analysed real-world data from a hospital-based administrative database in Japan. The main objective was to investigate the treatment of patients with haemophilia A in Japan, including the amounts of CFC and non-factor product (emicizumab) dispensed and the medical expenditures for patients who had consistent prescription fills of CFCs and without FVIII inhibitors.

Materials and Methods

Study Design

This was a retrospective, non-interventional, observational study of patients with haemophilia A included in the Medical Data Vision Co., Ltd (MDV) database, a large-scale, hospital-based, administrative database. The database contained inpatient hospitalization data, as well as outpatient and prescription data collected after a hospital visit unless the patient was transferred to another hospital. Data collected included outpatients and inpatient health insurance claims, costs, demographics, and limited laboratory data. As of February 2021, the database was the largest administrative database in Japan, with data from 438 facilities and > 35.2 million patients.

Study Population

Patients who met the following criteria were included: (1) evidence of visiting a healthcare facility in the database during the study period; (2) diagnosis of haemophilia A (ICD-10 code D66) during the study period, excluding an unconfirmed diagnosis; and (3) ≥ 2 prescriptions of the same CFC or emicizumab within the first 6 months of the index date and ≥ 2 weeks apart from each other during the study period, excluding the period during hospitalization. Exclusion criteria included patients who: (1) were diagnosed with congenital haemophilia with a FVIII inhibitor before the index date excluding unconfirmed diagnosis or (2) received bypass agents for treatment of haemophilia A with inhibitors after the index date.

The study period was from 1 January 2016 to 31 December 2020. The index date was defined as the date of the initial prescription fill of the CFC or emicizumab, with a record of the disease name being haemophilia A. Patients could have records pertaining to prescriptions for several CFCs or emicizumab that met this inclusion criterion in the patient’s medical history. Treatment duration was defined as the period from the first prescription fill of the CFC or emicizumab to the day before a switch to a different product, or it was censored at the last prescription of the same product if no switch occurred during the study period.

Outcome Measures

Treatment duration and annualized dosage in international units (IUs) per kilogram of body weight for CFC (with the calculation for body weight based on the statistical average weight of Japanese individuals in the specified age groups) [30] were summarized. The annual expenditures for CFC and emicizumab and the total healthcare expenditures were summarized in each year and in the overall period for patients receiving treatment with regular replacement therapy, defined as the use of CFC or emicizumab that met all of the following criteria: total treatment period of CFCs or emicizumab ≥ 1 year; prescription of any CFC or emicizumab ≥ two times on different dates during the year and no interval of > 6 months between prescriptions.

Data Analysis

Patient and treatment setting characteristics were summarized using descriptive statistics. Use of each CFC product (generic name) and emicizumab after the index date were summarized in each year and in the overall period for inpatients, outpatients and the whole population. For outpatient use, the percentage of patients who were prescribed a specific product at least once during the period was calculated in patients who could be followed during the period. Treatment duration and annualized dosage of each CFC (IU/kg) were summarized and, although the treatment duration could be censored, the summary of treatment duration was used for supporting the interpretation of the annualized dosage. All analyses were conducted for age subgroups 0–11, 12–19, 20–64 and ≥ 65 years.

Healthcare Expenditures

The annual expenditure for overall drug uses in the regular replacement therapy was summarized in each year and the overall period. The expenditures were also summarized separately by CFC and emicizumab. The total healthcare expenditure was summarized using the same method and included product and total medical costs (including medicine, testing/imaging, surgery, medical device/material, rehabilitation and other). Expenditures per product were derived from the Japanese drug price standard.

Switching from pdFVIII or rFVIII SHL Products to rFVIII EHL Products

Patients with data available for ≥ 3 months before and after switching from an SHL rFVIII (i.e. lonoctocog alfa, octocog alfa, octocog beta, rurioctocog alfa and turoctocog alfa) or pdFVIII product to an EHL rFVIII product (i.e. damoctocog alfa pegol, efraloctocog alfa, rurioctocog alfa pegol and turoctocog alfa pegol; i.e. the first occurrence of a switch to an EHL rFVIII product) and who filled ≥ 2 prescriptions for a EHL rFVIII product were included in the switching analyses.

The expenditures for CFC or emicizumab, total healthcare expenditures, and the summary statistic for product dosage (IU/kg) dispensed in the four quarters (3 months, 4–6 months, 7–9 months and 10–12 months) before and after switching were summarized. Incomplete quarters (i.e. patients with < 90 days’ follow-up) were not included.

Results

Study Population

Overall, 974 patients with haemophilia A on regular replacement therapy were included in the analysis (Fig. 1). Baseline demographics and characteristics are presented in Table 1. The median (range) age was 30.0 (0.0–91.0) years.Fig. 1 Study cohort selection. CFC clotting factor concentrate, FVIII factor VIII

Table 1 Patient demographics and baseline characteristics

Characteristics	Total (N = 974)	
Age (continuous, years)	
 Mean (SD)	31.1 (20.4)	
 Median (range), years	30.0 (0.0–91.0)	
Age category (years), n (%)	
 0–9	178 (18.3)	
 10–19	155 (15.9)	
 20–29	145 (14.9)	
 30–39	161 (16.5)	
 40–49	138 (14.2)	
 50–59	94 (9.7)	
 60–69	72 (7.4)	
 70–79	22 (2.3)	
 80+	9 (0.9)	
Comorbidities, n (%)	
 HIV	106 (10.9)	
 Viral hepatitis	448 (46.0)	
 Chronic viral hepatitis B	70 (7.2)	
 Chronic viral hepatitis C	408 (41.9)	
 Fibrosis and cirrhosis of liver	38 (3.9)	
 Malignant neoplasm of liver and intrahepatic bile ducts	101 (10.4)	
SD standard deviation

The median (first to third quartile) duration of follow-up for each patient was 3.7 (2.1–4.8) years. Patients visited university hospitals (41.2%), local public hospitals (27.7%), national hospitals (24.2%) and private hospitals (6.9%). The majority (67.4%) were medical institutions with ≥ 500 beds. A previous history of viral hepatitis and chronic viral hepatitis C was reported in 46.0% and 41.9% of the patients, respectively.

Usage of Each FVIII Product Dispensed in an Outpatient Setting

Following its launch in 2018, the proportion of patients dispensed emicizumab increased over the subsequent 2 years, with 17% of patients using emicizumab in 2019 and 25% in 2020 (Fig. 2). The percentage of patients who were dispensed EHL rFVIII/emicizumab also increased from 15% in 2016 to 72% in 2020; SHL rFVIII products were still used over the analysis period, with use of octocog beta notably increasing from 1% of patients in 2016 to 21% in 2020, whereas use of octocog alfa and rurioctocog alfa decreased over the analysis period. These trends were observed across all age categories [Fig. S1 in the Electronic Supplementary Material (ESM)].Fig. 2 Outpatient use of treatments for haemophilia A. EHL extended half-life, FVIII factor VIII, pdFVIII plasma-derived factor VIII, SHL standard half-life

Annualized Dosage for Each FVIII Product for Outpatient Use Only

Median annualized dispensed dosage (IU/kg) was lowest for pdFVIII products (901.9 IU/kg). Dispensed dosages of SHL rFVIII products ranged from 2022.4 to 4589.1 IU/kg (Table 2). The median annualized dispensed dosages for rFVIII EHL products ranged from 2189.1 to 2989.7 IU/kg (Table 2). Annualized FVIII dosage and observed treatment duration by age category are included in ESM Table S1. The treatment duration for each product varied (Table 2).Table 2 Observed treatment duration and annualized dosage of treatment for haemophilia A for outpatients (whole study population)

	SHL/plasma-derived products	EHL products	
Lonoctocog alfa
(n = 12)	Octocog alfa
(n = 190)	Octocog beta
(n = 217)	Rurioctocog alfa
(n = 392)	Turoctocog alfa
(n = 36)	pdFVIII
(n = 86)	Damoctocog alfa pegol
(n = 36)	Efraloctocog alfa
(n = 230)	Rurioctocog alfa pegol
(n = 192)	Turoctocog alfa pegol
(n = 2)	
Annualized FVIII dosage, median, IU/kg (Q1–Q3)	
	n = 13

4589.1 (1732.9– 5235.3)

	n = 203

2430.3 (1100.4–3997.1)

	n = 260

2022.4 (891.6–3803.8)

	n = 458

2091.7 (803.9–4484.3)

	n = 44

4280.8 (2096.0–5733.0)

	n = 89

901.9 (296.8–2791.7)

	n = 42

2989.7 (2262.7–3534.3)

	n = 357

2299.2 (838.4–4165.9)

	n = 226

2958.1 (1414.0–4538.6)

	n = 3

2189.1 (2167.5–7838.2)

	
Observed treatment duration, n (%)	
	n = 13	n = 203	n = 269	n = 461	n = 44	n = 91	n = 46	n = 372	n = 238	n = 3	
< 6 months	1 (7.7)	35 (17.2)	73 (27.1)	105 (22.8)	10 (22.7)	15 (16.5)	23 (50.0)	150 (40.3)	76 (31.9)	1 (33.3)	
6 to < 12 months	6 (46.2)	21 (10.3)	27 (10.0)	48 (10.4)	5 (11.4)	5 (5.5)	21 (45.7)	33 (8.9)	39 (16.4)	2 (66.7)	
1 to < 2 years	5 (38.5)	78 (38.4)	51 (19.0)	82 (17.8)	9 (20.5)	20 (22.0)	2 (4.4)	45 (12.1)	94 (39.5)	0	
2 to < 3 years	1 (7.7)	39 (19.2)	63 (23.4)	97 (21.0)	11 (25.0)	12 (13.2)	0	55 (14.8)	29 (12.2)	0	
≥ 3 years	0	30 (14.8)	55 (20.5)	129 (28.0)	9 (20.5)	39 (42.9)	0	89 (23.9)	0	0	
EHL extended half-life, FVIII factor VIII, Q quartile, SHL standard half-life

The n in the column heading is the number of unique patients that used the specified treatment

The n in the rows for annualized FVIII dosage and treatment duration is larger because an individual patient may have used a specified treatment multiple times at different time points

Prevalence of Joint Damage After the Index Date

Overall, 56.1% of patients had documented joint damage (Table 3), with the proportion of patients with joint damage increasing across age categories from 50.7% in those aged 0–11 years to 60.3% in those aged ≥ 65 years (ESM Table S2). The most frequent joint damage in the overall study population was haemophilic arthritis (Table 3).Table 3 Prevalence of joint damage after the index date in diseases with a frequency of ≥ 3% among the study population

Characteristics	Total (N = 974)	
Patients with joint damage, n (%)	546 (56.1)	
Prevalence rate of joint damage per 100 patient-years, rate (95% CI)	17.0 (15.0, 18.0)	
Types of joint damage, n (%)		
 Haemophilic arthritis	267 (27.4)	
 Ankle osteoarthritis	88 (9.0)	
 Foot arthralgia	86 (8.8)	
 Knee osteoarthritis	84 (8.6)	
 Gonalgia	74 (7.6)	
 Arthralgia	60 (6.2)	
 Coxarthrosis	51 (5.2)	
 Elbow osteoarthritis	50 (5.1)	
 Osteoarthritis	48 (4.9)	
 Hemarthrosis	46 (4.7)	
 Elbow arthralgia	40 (4.1)	
 Knee joint hematoma	39 (4.0)	
 Joint hematoma	38 (3.9)	
 Shoulder osteoarthritis	31 (3.2)	
SD standard deviation, CI confidence interval

Expenditures for Haemophilia A Treatments

Median annual total healthcare expenditure per patient increased twofold from ¥9,200,230 ($84,406 USD) in 2016 to ¥19,748,221 ($181,176 USD) in 2020 (Table 4). Annual expenditure per patient for CFC and emicizumab increased twofold from 2016 to 2020 [from ¥8,723,120 ($80,029 USD) to ¥18,051,689 ($165,612 USD)] and for CFC, increased 1.5-fold [from ¥8,642,905 ($79,293 USD) to ¥12,963,480 ($118,931 USD)]. For emicizumab, annual expenditure per patient increased 1.7-fold from 2018 when the product was launched to 2020 [2018: n = 4, ¥26,030,206 ($238,809 USD); 2019: n = 108, ¥29,919,696 ($274,493 USD); 2020: n = 107, ¥45,430,408 ($416,793 USD)]. Median annual total drug expenditure per patient with regular replacement therapy, as well as median annual expenditures for CFC, emicizumab and the total for each age category showed similar trends (ESM Table S3). The expenditures for products accounted for most of the annual total healthcare expenditures. Lower annual total healthcare expenditures were observed for patients without versus with joint damage (Table 4).Table 4 Mean (SD) and median (Q1–Q3) annual medical expenditures in Yen in patients receiving regular treatment for haemophilia A (whole study population)

Expenditure type	Overall
N = 974	2016
n = 482	2017
n = 697	2018
n = 706	2019
n = 785	2020
n = 796	
Annual expenditures for CFC and emicizumab treatment	n = 812	n = 435	n = 621	n = 600	n = 687	n = 637	
14,752,032 (11,150,277)	10,383,355 (8,573,035.5)	10,845,043 (8,678,315.4)	12,543,023 (9,736,055.2)	18,422,191 (14,716,020)	22,269,296 (17,285,885)	
12,506,400 (6,489,879–20,466,106)	8,723,120 (4,097,000–14,087,740)	9,017,408 (4,670,580–14,739,942)	10,920,408 (5,290,220–17,939,190)	14,763,450 (7,488,450–25,341,557)	1,80,51,689 (9,046,958–31,010,538)	
Annual expenditures for CFC treatment	n = 783	n = 434	n = 619	n = 595	n = 639	n = 524	
11,743,934 (8,540,374.7)	10,379,256 (8,582,502.5)	10,872,716 (8,678,630.3)	12,456,688 (9,468,396.2)	13,846,975 (10,293,331)	14,519,628 (10,834,696)	
10,533,673 (5,132,575–16,852,987)	8,642,905 (4,097,000–14,087,740)	9,046,240 (4,711,550–14,794,185)	10,911,048 (5,255,212–17,942,595)	12,204,090 (5,949,425–20,032,820)	1,29,63,480 (5,675,505–21,268,600)	
Annual expenditures for emicizumab treatment	n = 109	n = 0	n = 0	n = 4	n = 108	n = 107	
37,103,884 (15,931,933)	–	–	25,975,657 (14,829,865)	32,393,563 (17,512,794)	42,626,245 (18,062,399)	
38,554,180 (29,241,376–47,860,195)	–	–	26,030,206 (13,168,896–38,782,418)	29,919,696 (19,088,898–44,197,675)	45,430,408 (30,649,214–55,941,912)	
Annual total healthcare expenditures	n = 812	n = 435	n = 621	n = 600	n = 687	n = 637	
16,050,784 (11,619,619)	11,212,771 (9,152,752.7)	12,401,658 (9,284,991.2)	14,058,905 (10,371,648)	19,530,284 (15,199,782)	23,986,046 (17,153,416)	
13,955,966 (7,172,046–22,974,812)	9,200,230 (4,640,129–15,438,274)	10,726,590 (5,553,010–17,307,997)	12,201,220 (6,361,741–19,929,649)	15,689,073 (8,379,953–26,573,191)	19,748,221 (11,140,236–33,265,942)	
Annual total healthcare expenditures for patients with joint damage	n = 488	n = 300	n = 385	n = 378	n = 418	n = 401	
17,519,394 (11,983,558)	11,767,027 (9,557,487.6)	13,579,973 (9,666,177.6)	15,606,333 (11,016,181)	21,657,750 (15,948,875)	25,462,461 (17,632,073)	
15,334,449 (8,705,461–24,723,173)	10,073,543 (5,004,619–16,199,754)	11,793,884 (6,367,177–19,284,579)	13,668,982 (7,369,058–21,154,352)	17,843,240 (9,651,820–29,031,224)	21,402,753 (12,108,082–35,538,727)	
Total healthcare expenditure for patients without joint damage	n = 324	n = 135	n = 236	n = 222	n = 269	n = 236	
13,838,805 (10,691,832)	9,981,092.8 (8,079,893.3)	10,479,407 (8,293,870.4)	11,424,097 (8,571,622.9)	16,224,407 (13,325,186)	21,477,391 (16,034,684)	
11,380,764 (5,860,941–19,641,178)	8,328,629 (3,778,961–14,175,818)	8,840,388 (4,176,833–14,740,522)	10,096,693 (4,752,768–16,171,390)	12,888,284 (6,765,810–22,263,730)	17,328,835 (9,469,162–28,478,645)	
CFC clotting factor concentrate, Q quartile

Switch from pdFVIII/SHL rFVIII to EHL rFVIII Products

The breakdown of patients who switched from a pdFVIII or SHL rFVIII to an EHL rFVIII product is shown in Table 5. Overall, 23.9% (233/974) of patients switched from a pdFVIII or SHL rFVIII to an EHL rFVIII product during the study period, with the highest proportion of patients switching from rurioctocog alfa to either rurioctocog alfa pegol [106/233 (45.5%)] or efraloctocog alfa [40/233 (17.2%)]. There was an increase in the median amount of IUs prescribed in the first 3 months after switching product compared with the 3 months prior to switching although overall, there was no noticeable difference in the median IUs prescribed before and after switching (Fig. 3). However, median total healthcare expenditures (Fig. 4) and product expenditures (Fig. 5) increased after switching products.Table 5 Patients who switched from pdFVIII or SHL rFVIII to an EHL rFVIII product (n = 233)

	Damoctocog alfa pegol	Efraloctocog alfa	Rurioctocog alfa pegol	Turoctocog alfa pegol	
Octocog alfa	1 (0.4)	28 (12.0)	7 (3.0)	0	
Octocog beta	22 (9.4)	4 (1.7)	3 (1.3)	0	
Rurioctocog alfa	0	40 (17.2)	106 (45.5)	0	
Turoctocog alfa	0	8 (3.4)	1 (0.4)	1 (0.4)	
pdFVIII	0	9 (3.9)	3 (1.3)	0	
Data presented as n (%)

EHL extended half-life, FVIII factor VIII, pdFVIII plasma-derived factor VIII, SHL standard half-life

Fig 3 Median (Q1, Q3) FVIII IU/kg dispensed before and after switching from pdFVIII or SHL rFVIII to an EHL rFVIII product. EHL extended half-life, FVIII factor VIII, pdFVIII plasma-derived factor VIII, Q quartile, SHL standard half-life

Fig. 4 Median (Q1, Q3) total healthcare expenditures before and after switching from pdFVIII or SHL rFVIII to an EHL rFVIII product. EHL extended half-life, FVIII factor VIII, pdFVIII plasma-derived factor VIII, Q quarter, SHL standard half-life

Fig. 5 Median (Q1, Q3) expenditures for FVIII product before and after switching from pdFVIII or SHL rFVIII to an EHL rFVIII product. EHL extended half-life, FVIII factor VIII, pdFVIII plasma-derived factor VIII, Q quarter, SHL standard half-life

Discussion

This real-world study showed that IUs of EHL rFVIII products dispensed are increasing in Japan, with an accompanying increase in healthcare expenditures associated with switching from a pdFVIII or SHL rFVIII to an EHL rFVIII product. Overall, annual healthcare expenditures per patient with regular replacement therapy, as well as median annual expenditures for CFC, emicizumab and the total increased over the study. Annual expenditure over the analysis period was highest with emicizumab. An increase in overall drug expenditure was observed from 2018 when the emicizumab therapy was launched. On the basis of these results, it is predicted that the number of patients who receive emicizumab will increase, therefore haemophilia-related healthcare expenditure in Japan may also continue to rise. It is possible that the increases in annual healthcare expenditures in this study are related to overall inflation; however, the consumer price index in Japan increased only 2% over the study period (2016–2020) [31], which is much lower than the reported 1.5- to 2-fold increases in annual expenditures. In a real-world, multicentre, observational study in the USA, costs were decreased in patients with haemophilia with and without inhibitors following the initiation of emicizumab; however, the decrease was smaller in patients with haemophilia without inhibitors [32]. The difference between the current study in Japan and the study conducted in the USA could be the result of the high costs associated with the purchase of emicizumab in Japan.

The increase in median expenditures observed in the current analysis was similar to findings from other studies of patients with haemophilia A [21, 33, 34]. A budget impact model was developed to estimate the potential economic impact of switching from a pdFVIII/SHL rFVIII to an EHL rFVIII product in the USA [34]. The introduction of the EHL rFVIII product was estimated to have a budget impact of 1.4% across 2 years for a private payer population of 1,000,000 (estimated 19.7 individuals receiving treatment for haemophilia A) [34]. The introduction of EHL rFVIII was estimated to prevent 124 bleeds across 2 years at a cost of $1891 per bleed avoided [34]. In a real-world study conducted in a smaller population of patients with haemophilia A in the USA, median healthcare expenditures were higher over 2 years after patients switched from an SHL to an EHL rFVIII product. Switching to an EHL product was associated with variable factor IUs dispensed and consistently higher expenditures [21].

However, one budget impact analysis model did not predict increased costs with switching from a SHL to an EHL rFVIII product. A budget impact analysis to estimate the economic impact of the introduction of an EHL product, efmoroctocog alfa, for the treatment of haemophilia A in Italy suggested that the introduction of the EHL product did not result in higher expenditures in the Italian National Health System [35]. However, that model estimated treatment costs, whereas the current study explored real-world factor use.

Drug pricing in Japan considers the extended half-life of EHL products, thus EHL products are priced higher per IU than SHL products. For example, the price per IU of the EHL product Rurioctocog alfa pegol is approximately 40% greater than the price per IU of the SHL product Rurioctocog alfa. Typically, a decrease in the median FVIII IU/kg dispensed would be expected after a switch from a SHL to an EHL product; however, a similar or increasing trend in median IU/kg dispensed was observed in this study. Because EHL products are priced higher per IU than SHL products, this corresponded to an increase in treatment and total healthcare expenditures.

These findings suggest that there has been higher and/or more frequent dosing for EHL products than was originally assumed. There are several possible explanations for the observed increase in prescribing: the intensity of treatment for patients may have increased, previously undertreated patients may be adequately treated after switching, and/or patients may have improved adherence to prophylaxis after switching. Additionally, while the approved interval between doses is longer for EHL than SHL products, some patients may choose to follow a more frequent dosing schedule if they are not satisfied with the efficacy associated with the increased average half-life of EHL products. While this study did not examine the clinical outcomes of switching in these patients, more frequent dosing might be associated with improvements in patient quality of life.

There have been inconsistent reports regarding the impact of switching from prophylaxis with an SHL to an EHL rFVIII product on a patient’s health-related quality of life (HRQoL). In a retrospective chart review from a single haemophilia treatment centre in Canada [36], 38 boys (median age, 11.5 years) with moderate/severe haemophilia A who were switched from a SHL to an EHL product (reduction of 1.2 infusions/week) did not show any significant improvements in HRQoL, as measured on the Canadian Hemophilia Outcomes|–Kids’ Life Assessment Tool. However, in a prospective cohort study of persons with moderate or severe haemophilia aged ≥ 6 years, switching from a SHL to an EHL product resulted in short-term meaningful improvement in overall HRQoL and other patient-reported outcome measures, although the observed improvements disappeared by 24 months in most domains examined [37].

In the current study, approximately half of all young patients had some level of joint damage; the prevalence of joint damage then remained constant with ageing. This highlights that despite a relatively high standard of care for patients with haemophilia A in Japan, joint damage in the young population is still prevalent. Joint damage is a major complication associated with haemophilia, with a significant negative impact on quality of life for affected adults [38]. The Joint Outcomes Study demonstrated that joint outcomes in haemophilia are better in young adults if prophylaxis is started before age 2.5 years compared with after age 6 years [38]. This is an important consideration for all therapies to improve long-term joint outcomes.

There are several limitations of this study. First, the retrospective design precluded a more in-depth analysis of potential expenditure savings for various stakeholders, such as a decrease in hospitalizations and associated hospital-related expenditures. Second, treatment-related and broader medical expenditures may have been underestimated as only expenditures for medications dispensed in the hospital setting were included. Third, the diagnostic information in the database only includes data on patients who required in-hospital tests or treatment, and consequently may have under- or over-estimated the presence of comorbidities, such as chronic hepatitis, and the prevalence of joint damage; it therefore may not fully reflect real-world clinical practice. Lastly, the patient population in the database includes only those receiving treatment in the hospital. There may be differences in how patients are managed within a hospital versus a clinic setting, which will influence treatment patterns and expenditures, especially in the context of surgery and trauma. Another limitation could be the change from on-demand use to prophylaxis which may also increase costs, such as prophylactic therapy and hospital costs, over time.

Conclusions

This retrospective study found an increase in dispensing of EHL rFVIII versus SHL rFVIII or pdFVIII products among Japanese patients with haemophilia A, along with an increase in associated healthcare expenditures for patients who switched from a pdFVIII or SHL rFVIII to an EHL rFVIII product. Furthermore, healthcare expenditure increased along with the increase of emicizumab use after its launch in 2018. Overall, these results provide insight into the treatment and expenditures associated with haemophilia A in Japan and highlight the disease burden in patients requiring hospital care.

Supplementary Information

Below is the link to the electronic supplementary material.Supplementary file1 (PDF 571 kb)

Acknowledgements

Editorial support was provided by Marion James, Ph.D., CMPP, of Engage Scientific Solutions (Horsham, UK) and was funded by Pfizer.

Declarations

Funding

This study was sponsored by Pfizer.

Conflict of Interest

Katsuyuki Fukutake has received honoraria from and/or served as a member of an advisory board or speakers’ bureau for Bayer Yakuhin, Chugai Pharmaceutical, Fujimoto Pharmaceutical, Pfizer Japan Inc., Sanofi, CellGenTech and Takeda. Masato Bingo has received honoraria or research funding from and/or served as a member of an advisory board or speakers’ bureau for Bayer Yakuhin, Chugai Pharmaceutical, KM Biologics, Novo Nordisk, Pfizer Japan Inc., Sanofi and Takeda. Kanae Togo, Linghua Xu and Toshiyuki Karumori are employees of Pfizer Japan Inc. and may own stock/options in the company. José Maria Jimenez Alvir is an employee of Pfizer Inc. and may own stock/options in the company. Ian Winburn is an employee of Pfizer Ltd and may own stock/options in the company.

Availability of Data and Material

The data that support the findings of this study are available from the corresponding author, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data may however be available from the authors upon reasonable request and with permission of Medical Data Vision Co., Ltd, Tokyo.

Code Availability

Not applicable.

Ethics Approval

This study was conducted in accordance with legal and regulatory requirements in Japan. It used anonymized claims data with no personal patient information included and, as per Japanese Ethical Guidelines for Medical and Biological Research Involving Human Subjects, review by an institutional review board or ethics committee was not required.

Consent to Participate

Not applicable.

Consent to Publish

Not applicable.

Author Contributions

M.B., K.F., K.T., L.X. and T.K. were responsible for the study concept and design. M.B., K.F., K.T., L.X., J.M.J.A., I.W. and T.K. had full access to the data and were responsible for data interpretation. All authors contributed to the drafting, critical review and revision of the manuscript, with the support of medical writers provided by Pfizer Inc. All authors have read and approved the final submitted manuscript and agree to be accountable for the work.
==== Refs
References

1. Franchini M Mannucci PM Past, present and future of hemophilia: a narrative review Orphanet J Rare Dis 2012 7 24 10.1186/1750-1172-7-24 22551339
Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis. 2012;7:24.22551339 10.1186/1750-1172-7-24
2. Peyvandi F Garagiola I Young G The past and future of haemophilia: diagnosis, treatments, and its complications Lancet 2016 388 187 197 10.1016/S0140-6736(15)01123-X 26897598
Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016;388:187–97.26897598 10.1016/S0140-6736(15)01123-X
3. World Federation of Hemophilia. World Federation of Hemophilia Report on the Annual Global Survey 2020. 2020. https://www1.wfh.org/publications/files/pdf-2045.pdf?_gl=1*1n5ywh9*_ga*Nzc1NTUwMjk5LjE2NDMyMDU1MDc.*_ga_7974KH9LH5*MTY0NTQ1NTMwMy4yLjAuMTY0NTQ1NTMwMy4w&_ga=2.10328053.1592376959.1645455304-775550299.1643205507. Accessed 16 Jan 2024.
4. Aledort L Mannucci PM Schramm W Tarantino M Factor VIII replacement is still the standard of care in haemophilia A Blood Transfus 2019 17 479 486 31846611
Aledort L, Mannucci PM, Schramm W, Tarantino M. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfus. 2019;17:479–86.31846611
5. Damoctocog alfa pegol package insert (Japan). 2018. https://www.info.pmda.go.jp/go/pack/6343453D1020_1_04/?view=frame&style=XML&lang=ja. Accessed 19 January 2024.
6. Efraloctocog alfa package insert (Japan). 2014. https://www.info.pmda.go.jp/go/pack/6343442D1022_3_04/?view=frame&style=XML&lang=ja. Accessed 19 Jan 2024.
7. Rurioctocog alfa pegol package insert (Japan). 2016. https://www.info.pmda.go.jp/go/pack/6343446G1027_2_03/?view=frame&style=XML&lang=ja. Accessed 19 Jan 2024.
8. Turoctocog alfa pegol package insert (Japan). 2019. https://www.info.pmda.go.jp/go/pack/6343454D1025_1_02/?view=frame&style=XML&lang=ja. Accessed 16 Jan 2024.
9. Emicizumab Japanese Regulatory Review. 2018. https://www.pmda.go.jp/files/000236236.pdf. Accessed 16 Jan 2024.
10. Uchida N Sambe T Yoneyama K A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects Blood 2016 127 1633 1641 10.1182/blood-2015-06-650226 26626991
Uchida N, Sambe T, Yoneyama K, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016;127:1633–41.26626991 10.1182/blood-2015-06-650226
11. Shima M Hanabusa H Taki M Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A N Engl J Med 2016 374 2044 2053 10.1056/NEJMoa1511769 27223146
Shima M, Hanabusa H, Taki M, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016;374:2044–53.27223146 10.1056/NEJMoa1511769
12. Shima M Hanabusa H Taki M Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors Blood Adv 2017 1 1891 1899 10.1182/bloodadvances.2017006684 29296836
Shima M, Hanabusa H, Taki M, et al. Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors. Blood Adv. 2017;1:1891–9.29296836 10.1182/bloodadvances.2017006684
13. Oldenburg J Mahlangu JN Kim B Emicizumab prophylaxis in hemophilia A with inhibitors N Engl J Med 2017 377 809 818 10.1056/NEJMoa1703068 28691557
Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377:809–18.28691557 10.1056/NEJMoa1703068
14. Mahlangu J Oldenburg J Paz-Priel I Emicizumab prophylaxis in patients who have hemophilia A without inhibitors N Engl J Med 2018 379 811 822 10.1056/NEJMoa1803550 30157389
Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379:811–22.30157389 10.1056/NEJMoa1803550
15. Balkaransingh P Young G Novel therapies and current clinical progress in hemophilia A Ther Adv Hematol. 2018 9 49 61 10.1177/2040620717746312 29387330
Balkaransingh P, Young G. Novel therapies and current clinical progress in hemophilia A. Ther Adv Hematol. 2018;9:49–61.29387330 10.1177/2040620717746312
16. Machin N Ragni MV Smith KJ Gene therapy in hemophilia A: a cost-effectiveness analysis Blood Adv 2018 2 1792 1798 10.1182/bloodadvances.2018021345 30042145
Machin N, Ragni MV, Smith KJ. Gene therapy in hemophilia A: a cost-effectiveness analysis. Blood Adv. 2018;2:1792–8.30042145 10.1182/bloodadvances.2018021345
17. Collins PW Personalized prophylaxis Haemophilia 2012 18 Suppl 4 131 135 10.1111/j.1365-2516.2012.02838.x 22726096
Collins PW. Personalized prophylaxis. Haemophilia. 2012;18(Suppl 4):131–5.22726096 10.1111/j.1365-2516.2012.02838.x
18. Mancuso ME Santagostino E Outcome of clinical trials with new extended half-life FVIII/IX concentrates J Clin Med 2017 6 39 10.3390/jcm6040039 28350322
Mancuso ME, Santagostino E. Outcome of clinical trials with new extended half-life FVIII/IX concentrates. J Clin Med. 2017;6:39.28350322 10.3390/jcm6040039
19. Shapiro AD Ragni MV Kulkarni R Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels J Thromb Haemost 2014 12 1788 1800 10.1111/jth.12723 25196897
Shapiro AD, Ragni MV, Kulkarni R, et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost. 2014;12:1788–800.25196897 10.1111/jth.12723
20. Miners AH Krishnan S Pasi KJ Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis J Thromb Haemost 2016 14 2141 2147 10.1111/jth.13440 27510890
Miners AH, Krishnan S, Pasi KJ. Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis. J Thromb Haemost. 2016;14:2141–7.27510890 10.1111/jth.13440
21. Chhabra A Fogarty PF Tortella BJ Real-world analysis of dispensed international units of coagulation factor VIII and resultant expenditures for hemophilia A patients: a comparison between standard half-life and extended half-life products Manag Care 2018 27 39 50 30309448
Chhabra A, Fogarty PF, Tortella BJ, et al. Real-world analysis of dispensed international units of coagulation factor VIII and resultant expenditures for hemophilia A patients: a comparison between standard half-life and extended half-life products. Manag Care. 2018;27:39–50.30309448
22. Bowen K Borchardt M Gleason P Incremental cost of switching to extended half-life coagulation factor products to treat hemophilia among 15 million commercially insured members J Manag Care Spec Pharm 2018 24 S33 S34
Bowen K, Borchardt M, Gleason P. Incremental cost of switching to extended half-life coagulation factor products to treat hemophilia among 15 million commercially insured members. J Manag Care Spec Pharm. 2018;24:S33–4 (Abstract D4).
23. Bullement A McMordie ST Hatswell AJ Cost-effectiveness analysis of recombinant factor VIII Fc-fusion protein (rFVIIIFc) for the treatment of severe hemophilia A in Italy incorporating real-world dosing and joint health data Pharmacoecon Open 2020 4 133 142 10.1007/s41669-019-0158-8 31280415
Bullement A, McMordie ST, Hatswell AJ, et al. Cost-effectiveness analysis of recombinant factor VIII Fc-fusion protein (rFVIIIFc) for the treatment of severe hemophilia A in Italy incorporating real-world dosing and joint health data. Pharmacoecon Open. 2020;4:133–42.31280415 10.1007/s41669-019-0158-8
24. Cortesi PA D'Angiolella LS Lafranconi A Modern treatments of haemophilia: review of cost-effectiveness analyses and future directions Pharmacoeconomics 2018 36 263 284 10.1007/s40273-017-0588-z 29170896
Cortesi PA, D’Angiolella LS, Lafranconi A, et al. Modern treatments of haemophilia: review of cost-effectiveness analyses and future directions. Pharmacoeconomics. 2018;36:263–84.29170896 10.1007/s40273-017-0588-z
25. Guh S Grosse SD McAlister S Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008 Haemophilia 2012 18 268 275 10.1111/j.1365-2516.2011.02692.x 22151000
Guh S, Grosse SD, McAlister S, et al. Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008. Haemophilia. 2012;18:268–75.22151000 10.1111/j.1365-2516.2011.02692.x
26. Gong GW Chen YC Fang PQ Min R Correction to: Medical expenditure for patients with hemophilia in urban China: data from medical insurance information system from 2013 to 2015 Orphanet J Rare Dis 2020 15 239 10.1186/s13023-020-01524-3 32900391
Gong GW, Chen YC, Fang PQ, Min R. Correction to: Medical expenditure for patients with hemophilia in urban China: data from medical insurance information system from 2013 to 2015. Orphanet J Rare Dis. 2020;15:239.32900391 10.1186/s13023-020-01524-3
27. Gong GW Chen YC Fang PQ Min R Medical expenditure for patients with hemophilia in urban China: data from medical insurance information system from 2013 to 2015 Orphanet J Rare Dis 2020 15 137 10.1186/s13023-020-01423-7 32503636
Gong GW, Chen YC, Fang PQ, Min R. Medical expenditure for patients with hemophilia in urban China: data from medical insurance information system from 2013 to 2015. Orphanet J Rare Dis. 2020;15:137.32503636 10.1186/s13023-020-01423-7
28. Malhan S Oksuz E Antmen B Cost of hemophilia A in Turkey: an economic disease burden analysis J Med Econ 2021 24 1052 1059 10.1080/13696998.2021.1965388 34355649
Malhan S, Oksuz E, Antmen B, et al. Cost of hemophilia A in Turkey: an economic disease burden analysis. J Med Econ. 2021;24:1052–9.34355649 10.1080/13696998.2021.1965388
29. Tu TC Cheng SN Chen JD Economic burden of high-responding inhibitors in patients with hemophilia A in Taiwan Yonsei Med J 2013 54 358 365 10.3349/ymj.2013.54.2.358 23364968
Tu TC, Cheng SN, Chen JD, et al. Economic burden of high-responding inhibitors in patients with hemophilia A in Taiwan. Yonsei Med J. 2013;54:358–65.23364968 10.3349/ymj.2013.54.2.358
30. e-Stat. National Health and Nutrition Survey. 2018. https://www.e-stat.go.jp/dbview?sid=0003224177. Accessed 16 Jan 2024.
31. The World Bank. Inflation, consumer prices (annual %)—Japan. https://data.worldbank.org/indicator/FP.CPI.TOTL.ZG?end=2020&locations=JP&start=2016&view=chart. Accessed 16 Jan 2024.
32. Samelson-Jones BJ Guelcher C Kuhn J Real-world cost estimates of initiating emicizumab in US patients with haemophilia A Haemophilia 2021 27 591 598 10.1111/hae.14347 34050689
Samelson-Jones BJ, Guelcher C, Kuhn J, et al. Real-world cost estimates of initiating emicizumab in US patients with haemophilia A. Haemophilia. 2021;27:591–8.34050689 10.1111/hae.14347
33. Song X Liu W Xue F Real-world analysis of haemophilia patients in China: a single centre's experience Haemophilia 2020 26 584 590 10.1111/hae.14029 32432832
Song X, Liu W, Xue F, et al. Real-world analysis of haemophilia patients in China: a single centre’s experience. Haemophilia. 2020;26:584–90.32432832 10.1111/hae.14029
34. McMullen S Buckley B Hall E 2nd Budget impact analysis of prolonged half-life recombinant FVIII therapy for hemophilia in the United States Value Health 2017 20 93 99 10.1016/j.jval.2016.09.2396 28212975
McMullen S, Buckley B, Hall E 2nd, et al. Budget impact analysis of prolonged half-life recombinant FVIII therapy for hemophilia in the United States. Value Health. 2017;20:93–9.28212975 10.1016/j.jval.2016.09.2396
35. Lorenzoni V Triulzi I Turchetti G Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective BMC Health Serv Res 2018 18 596 10.1186/s12913-018-3398-x 30071878
Lorenzoni V, Triulzi I, Turchetti G. Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective. BMC Health Serv Res. 2018;18:596.30071878 10.1186/s12913-018-3398-x
36. Carcao M Zunino L Young NL Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: lessons learned with the CHO-KLAT tool Haemophilia 2020 26 73 78 10.1111/hae.13905 31865620
Carcao M, Zunino L, Young NL, et al. Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: lessons learned with the CHO-KLAT tool. Haemophilia. 2020;26:73–8.31865620 10.1111/hae.13905
37. Sun HL Yang M Poon MC The impact of extended half-life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B Res Pract Thromb Haemost. 2021 5 e12601 10.1002/rth2.12601 34667922
Sun HL, Yang M, Poon MC, et al. The impact of extended half-life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B. Res Pract Thromb Haemost. 2021;5: e12601.34667922 10.1002/rth2.12601
38. O'Hara J Walsh S Camp C The impact of severe haemophilia and the presence of target joints on health-related quality-of-life Health Qual Life Outcomes 2018 16 84 10.1186/s12955-018-0908-9 29720192
O’Hara J, Walsh S, Camp C, et al. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health Qual Life Outcomes. 2018;16:84.29720192 10.1186/s12955-018-0908-9
